Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-04-08
DOI
10.3389/fphar.2022.849758
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases
- (2021) Charles Khouri et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
- (2021) Roger S. McIntyre et al. AMERICAN JOURNAL OF PSYCHIATRY
- Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis
- (2021) Sheng-Min Wang et al. Clinical Psychopharmacology and Neuroscience
- Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders
- (2021) Felicia Ceban et al. CNS DRUGS
- The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database
- (2021) Faizan Mazhar et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies
- (2020) Wei Zheng et al. JOURNAL OF AFFECTIVE DISORDERS
- Are we repeating mistakes of the past? A review of the evidence for esketamine
- (2020) Mark A. Horowitz et al. BRITISH JOURNAL OF PSYCHIATRY
- Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system
- (2020) Milo Gatti et al. European Journal of Preventive Cardiology
- Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database
- (2020) Natalia Gonzalez Caldito et al. Multiple Sclerosis Journal
- Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
- (2020) Chiara Gastaldon et al. PSYCHOTHERAPY AND PSYCHOSOMATICS
- Increased use of ketamine for the treatment of depression: Benefits and concerns
- (2020) Kyoung-Sae Na et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis
- (2020) Jiaqi Xiong et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Polypharmacy in a hospitalized psychiatric population: risk estimation and damage quantification
- (2019) J. Carmona-Huerta et al. BMC Psychiatry
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
- (2019) Vanina Popova et al. AMERICAN JOURNAL OF PSYCHIATRY
- A Word to the Wise About Intranasal Esketamine
- (2019) Alan F. Schatzberg AMERICAN JOURNAL OF PSYCHIATRY
- Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class
- (2019) Jean Kim et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
- (2019) Douglas B. Johnson et al. Journal for ImmunoTherapy of Cancer
- Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
- (2019) Maggie Fedgchin et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression
- (2019) Ella J. Daly et al. JAMA Psychiatry
- Time‐to‐onset analysis of amiodarone‐associated thyroid dysfunction
- (2019) Sayoko Kinoshita et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3
- (2019) Rachel Ochs-Ross et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Esketamine: A Novel Option for Treatment-Resistant Depression
- (2019) Kevin M. Bozymski et al. ANNALS OF PHARMACOTHERAPY
- Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems
- (2018) E. Raschi et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study
- (2018) Randall L. Morrison et al. PSYCHOPHARMACOLOGY
- A characterization and disproportionality analysis of medication error related adverse events reported to the FAERS database
- (2018) Carla Carnovale et al. Expert Opinion On Drug Safety
- Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
- (2018) Joe-Elie Salem et al. LANCET ONCOLOGY
- Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems
- (2017) E. Raschi et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories
- (2016) T. Kishimoto et al. PSYCHOLOGICAL MEDICINE
- An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies
- (2015) Miguel-Angel Maciá-Martínez et al. DRUG SAFETY
- The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010
- (2014) Keith B. Hoffman et al. DRUG SAFETY
- Gender differences in abusers of amphetamine-type stimulants and ketamine in southwestern China
- (2012) Yangyang Zhang et al. ADDICTIVE BEHAVIORS
- Relationship of Ketamine's Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression
- (2012) Carlos A. Zarate et al. BIOLOGICAL PSYCHIATRY
- The prevalence and natural history of urinary symptoms among recreational ketamine users
- (2012) Adam R. Winstock et al. BJU INTERNATIONAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started